Infographics - Hemophilia Treatment Market

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low–middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study:

This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemophilia treatment market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market

Detailed Segmentation:

Global Hemophilia Treatment Market, By Product Type:
- Plasma Derived Coagulation Factor
- Recombinant Coagulation Factor
- Antifibrinolytic Agents
- Desmopressin
Global Hemophilia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hemophilia Treatment Market, By Region:
- North America
  - By Country:
    - U.S.
    - Canada
- Latin America
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country:
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Takeda Pharmaceutical Co., Ltd*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sanofi S.A.
- Octapharma AG
- Swedish Orphan Biovitrum AB
- Baxter International Inc.
- Biogen Inc
- Bayer AG
- CSL Behring
- Ferring B.V.
- Pfizer, Inc.
- Kedrion
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Product Type
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
Global Hemophilia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
Global Hemophilia Treatment Market, By Product Type, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017– 2030
  - Segment Trends
- Recombinant Coagulation Factor
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Plasma Derived Coagulation Factor
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Antifibrinolytic Agents
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Desmopressin
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Global Hemophilia Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Global Hemophilia Treatment Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, For Region, 2017–2030
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Takeda Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sanofi S.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Octapharma AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Swedish Orphan Biovitrum AB
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Baxter International Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- CSL Behring
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Ferring B.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kedrion
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
Section
- Research Methodology
- About Us

*Browse 35 market data tables and 34 figures on “Global Hemophilia Treatment Market” -Global forecast to 2030

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

HEMOPHILIA TREATMENT MARKET ANALYSIS

Hemophilia Treatment Market

Need a Custom Report?

EXISTING CLIENTELE